Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders (OPAL)
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR®) as Mono-Therapy in the Treatment of Adult Patients With Major Depressive Disorder
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States
- Research Site
-
-
Arkansas
-
Little Rock, Arkansas, United States
- Research Site
-
-
California
-
Anaheim, California, United States
- Research Site
-
El Centro, California, United States
- Research Site
-
Garden Grove, California, United States
- Research Site
-
National City, California, United States
- Research Site
-
Riverside, California, United States
- Research Site
-
-
Connecticut
-
Hartford, Connecticut, United States
- Research Site
-
-
Delaware
-
Wilmington, Delaware, United States
- Research Site
-
-
Florida
-
Altamonte Springs, Florida, United States
- Research Site
-
DeLand, Florida, United States
- Research Site
-
Maitland, Florida, United States
- Research Site
-
New Port Richey, Florida, United States
- Research Site
-
-
Georgia
-
Atlanta, Georgia, United States
- Research Site
-
Decatur, Georgia, United States
- Research Site
-
Roswell, Georgia, United States
- Research Site
-
-
Illinois
-
Naperville, Illinois, United States
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, United States
- Research Site
-
Lafayette, Indiana, United States
- Research Site
-
-
Kentucky
-
Owensboro, Kentucky, United States
- Research Site
-
-
Louisiana
-
New Orleans, Louisiana, United States
- Research Site
-
-
Massachusetts
-
Braintree, Massachusetts, United States
- Research Site
-
Cambridge, Massachusetts, United States
- Research Site
-
Pittsfield, Massachusetts, United States
- Research Site
-
-
Minnesota
-
Minneapolis, Minnesota, United States
- Research Site
-
-
Missouri
-
St. Louis, Missouri, United States
- Research Site
-
-
New York
-
Staten Island, New York, United States
- Research Site
-
-
Ohio
-
Avon Lake, Ohio, United States
- Research Site
-
Cincinnati, Ohio, United States
- Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States
- Research Site
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States
- Research Site
-
-
Tennessee
-
Memphis, Tennessee, United States
- Research Site
-
-
Texas
-
DeSoto, Texas, United States
- Research Site
-
Houston, Texas, United States
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient is able to provide written informed consent before beginning any study related procedures
- Patient has a documented clinical diagnosis of major depressive disorder
- Patient is able to understand and comply with the requirements of the study, as judged by a study investigator
Exclusion Criteria:
- Patients with a history of non-compliance as judged by the study investigator
- Patients with a known lack of response to previous treatment with quetiapine
- Patients who have participated in a clinical trial within 4 weeks of randomization
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
To evaluate the efficacy of Quetiapine SR compared with placebo in the treatment of patients with MDD as assessed by change from randomization to Week 8 in the MADRS total score
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
To evaluate if Quetiapine SR improves the health-related quality of life of patients with MDD, compared to placebo
|
|
To evaluate if quetiapine SR reduces anxiety symptoms in patients with MDD, compared to placebo
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- McIntyre RS, Gorwood P, Thase ME, Liss C, Desai D, Chen J, Bauer M. Early Symptom Improvement as a Predictor of Response to Extended Release Quetiapine in Major Depressive Disorder. J Clin Psychopharmacol. 2015 Dec;35(6):706-10. doi: 10.1097/JCP.0000000000000416.
- Weisler R, Montgomery SA, Earley WR, Szamosi J, Eriksson H. Extended release quetiapine fumarate in patients with major depressive disorder: suicidality data from acute and maintenance studies. J Clin Psychiatry. 2014 May;75(5):520-7. doi: 10.4088/JCP.13m08624.
- Weisler R, McIntyre RS. The role of extended-release quetiapine fumarate monotherapy in the treatment of patients with major depressive disorder. Expert Rev Neurother. 2013 Nov;13(11):1161-82. doi: 10.1586/14737175.2013.846520.
- Clayton AH, Locklear JC, Svedsater H, McIntyre RS. Sexual functioning in patients with major depressive disorder in randomized placebo-controlled studies of extended release quetiapine fumarate. CNS Spectr. 2014 Apr;19(2):182-96. doi: 10.1017/S1092852913000631. Epub 2013 Sep 25.
- Thase ME, Montgomery S, Papakostas GI, Bauer M, Trivedi MH, Svedsater H, Locklear JC, Gustafsson U, Datto C, Eriksson H. Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy. Int Clin Psychopharmacol. 2013 May;28(3):113-20. doi: 10.1097/YIC.0b013e32835fb971.
- Bortnick B, El-Khalili N, Banov M, Adson D, Datto C, Raines S, Earley W, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord. 2011 Jan;128(1-2):83-94. doi: 10.1016/j.jad.2010.06.031. Epub 2010 Aug 6.
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- D1448C00003
- Opal
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.